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Rupture-prone unstable arterial plaques develop con-
comitantly with the appearance of intraplaque hem-
orrhage and tissue ulceration, in association with de-
regulation of smooth muscle cell mitogenesis and
leakage of newly formed blood vessels. Using mi-
croarray technology, we have identified novel pro-
tein deregulation associated with unstable carotid
plaque regions. Overexpression of proapoptotic pro-
teins caspase-9 and TRAF4 was seen in endothelial
cells and smooth muscle cells from unstable hemor-
rhagic and ulcerated plaque regions. Topoisomerase-
II- (TOPO-II-), which is associated with DNA repair
mechanisms, was also overexpressed by these cells.
Cell signaling molecules c-src, G-protein-coupled re-
ceptor kinase-interacting protein (GIT1), and c-jun
N-terminal kinase (JNK) were up-regulated in endo-
thelial cells from the same areas, whereas an increase
in expression of junctional adhesion molecule-1
(JAM-1) in blood vessels and infiltrating macrophages
from inflammatory regions might form part of a leu-
kocyte rolling response, increasing the plaque vol-
ume. Grb2-like adaptor protein (Gads), responsible
for differentiation of monocytes into macrophages,
was expressed by macrophages from unstable
plaques, suggesting a potential mechanism through
which increased scavenging could occur in rupture-
prone areas. We conclude that modulation of novel
cell signaling intermediates, such as those described
here, could be useful in the therapy of angiogenesis
and apoptosis, designed to reduce unstable plaque
formation. (Am J Pathol 2006, 168:1004–1021; DOI:
10.2353/ajpath.2006.050471)
Carotid artery atherosclerosis is the primary mediator of
ischemic stroke, which is a leading cause of death and
disability in the Western world. The development of
symptoms follows conversion of stable plaques to unsta-
ble ones, concomitant with the appearance of in-
traplaque hemorrhage, fibrous cap thinning, and infiltra-
tion with macrophages and T cells, as well as surface
ulceration and rupture and thrombosis. Specifically, un-
stable plaques may be identified by Echo-Doppler ultra-
sonography and histological American Heart Association
criteria of recent ulceration and hemorrhage.1 The patho-
biological mechanisms responsible for this conversion
include increased inflammation and angiogenesis as well
as changes in the rate of and resistance of cells to
apoptosis.1,2 The molecular mechanisms responsible
for induction of these changes have not been fully
described.
Elevated concentrations of proinflammatory markers
including intracellular adhesion molecule-1,3 matrix met-
alloproteinase-9,4 interleukin-18,5 and tumor necrosis
factor (TNF)-6 have been implicated in the progression
of asymptomatic to symptomatic plaques. A reduction in
expression of platelet-activating factor receptor suggests
a reduction in the capacity for defense associated with
loss of the macrophage inflammatory phenotype.7 Over-
expression of growth factors and cytokines produced as
a consequence of the inflammatory process induces sig-
nal transduction activity, which impacts on the critical
pathways of angiogenesis and apoptosis within develop-
ing plaque tissue.
Angiogenesis is a recognized feature of the athero-
genic process, with intimal neovascularization arising
most frequently from the dense network of vessels in the
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adventitia, adjacent to a plaque, rather than from the
main artery lumen.2 New blood vessels may have an
active role in plaque metabolic activity and actively pro-
mote its growth beyond the critical limits of diffusion from
the artery lumen.8 Later in the progression of disease, the
inherent weakness of newly forming blood vessels could
result in development of intraplaque hemorrhage and
instability.9 A strong correlation between areas of in-
creased vascularity and intraplaque hemorrhage has
been demonstrated by histological staining with anti-
CD34 in symptomatic patients after endarterectomy.10
The irregular nature of blood vessel formation has been
likened to tumor angiogenesis, and hence the factors
responsible for their growth may be different from those
seen during normal wound healing.11 Plaque-associated
endothelial cells (ECs) become activated, associate with
monocytes and macrophages, and show increased ex-
pression of adhesion molecules. Thus, they may also be
at least partly responsible for induction of the inflamma-
tion associated with neurological symptoms.12
Apoptosis of the cellular components within suscepti-
ble atherosclerotic lesions can increase the likelihood of
plaque rupture by increase in the lipid core volume,
thinning the fibrous cap, reduction in concentration of
interstitial collagen fibers [due to smooth muscle cell
(SMC) apoptosis], and production of leaky microvessels
(EC apoptosis), resulting in hemorrhage.13 Both vascular
SMCs and ECs found in unstable lesions overexpress
proapoptotic proteins such as Fas ligand and Bax with a
propensity for down-regulation of anti-apoptotic counter-
parts such as Bcl-2.14,15 Animal models have been used
to identify some deregulated intermediates. For example,
plaques induced in cholesterol-fed rabbits demonstrated
increased staining of both c-jun N-terminal kinase (JNK)
and phosphorylated p53 in macrophages undergoing
apoptosis in lesional cap and basal regions.16 Global
gene apoptosis-specific microarray studies comparing
nonatherosclerotic and atherosclerotic carotid arteries
have also identified novel mediators including death-
associated protein (DAP) kinase in foam cells of SMC
origin.17
As mentioned above, the signaling mechanisms re-
sponsible for cellular changes resulting in plaque insta-
bility have not been fully determined. Previous studies
have used global gene microarray analysis to measure
changes in mRNA expression in plaque samples; how-
ever, evidence suggests that a significant number of
gene products are not translated, and the correlation
between mRNA and protein concentration is often
poor.17–19 More recently, Western array analysis was
used to compare protein expression in normal mammary
artery and human carotid artery specimens.20 The au-
thors demonstrated down-regulation of a novel proapop-
totic protein, apoptosis-linked gene-2 (ALG-2), in plaque
samples and postulated that it could provide a survival
mechanism and protect against plaque rupture.
In the present study, we have used protein microarrays
to compare protein expression in carotid endarterectomy
samples histologically defined as stable and unstable.
Relevant deregulated proteins were confirmed by West-
ern blotting, including comparison with a series of normal
carotid artery specimens obtained at transplant. We iden-
tified overexpression of several novel proteins that could
impact both angiogenesis/cell proliferation (junctional
adhesion molecule-1 or JAM-1, G protein-coupled recep-
tor kinase-interacting protein or GIT1, and c-src) and
apoptosis (topoisomerase-II- or TOPO-II-, caspase-9,
TNF receptor-activating factor-4 or TRAF4, Grb2-like
adaptor protein or GADS, and JNK), in promoting plaque
instability and thrombosis.
Materials and Methods
Materials
Glass protein microarrays containing 512 antibody sets
(in duplicate) were obtained from BD Biosciences (Clon-
tech, Buckinghamshire, UK). Cy3/Cy5 NHS-esters used
for protein labeling and disposable PD-10 desalting col-
umns were from Amersham Biosciences, UK. The follow-
ing antibodies used for Western blotting and immunohis-
tochemistry were obtained from Autogen Bioclear
(Wiltshire, UK) and were rabbit polyclonal unless other-
wise stated: anti-c-src, anti-JAM-1 (mouse monoclonal),
anti-GIT1, anti-TOPO-II-, anti-JNK, anti-caspase-9, anti-
TNF-, anti-GADS, anti-TRAF4, EC marker anti-CD105
(R&D Systems, Abingdom, UK), SMC marker anti-SMC-
actin (Sigma Chemicals, Dorset, UK), and macrophage
marker anti-CD64. Bio-Rad protein detection reagent was
from Bio-Rad (Hercules, CA). Vectastain ABC kit was
from Vector Laboratories, UK. All other materials and
chemicals were from Sigma Chemicals.
Carotid Endarterectomy Specimens
Human carotid endarterectomy specimens (n 17) were
obtained from patients with a significant degree of carotid
stenosis (70%), as demonstrated by duplex ultrasonog-
raphy. Extensive neurological examination was used to
determine stable/asymptomatic/unstable/symptomatic
subgroups. The lesion was considered symptomatic
when associated with transitory or established neurolog-
ical deficits. Computed tomography scans were consid-
ered positive when cerebral infarcts were present in the
area of the ipsilateral territory of cerebral arteries. All
patients had Echo-Doppler on admission (before sur-
gery) and 6 months later. Clinical and biochemical details
are listed in Tables 1 and 2. The specimens were opened
longitudinally and divided into two pieces, one fixed in
10% formaldehyde and the other frozen at 80°C for use
in protein arrays and Western blotting. Nonatheroscle-
rotic carotid artery specimens (n 7) were obtained from
age-matched individuals and obtained during transplant
bypass surgery. All patients gave consent for the use of
their plaque and blood samples for research analysis.
Tissue acquisition and subsequent use were approved
by the local ethical committee.
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Table 1. Characteristics of Study Patients Used in Microarray Studies and Western Blotting
Patient
no.
Age,
year
Sex,
M/F
Stable
(n  5)
Unstable
(n  12)
Plaque
ulceration
Intraplaque
hemorrhage Fibrotic Symptomatic
22 78 M Stable Yes Yes No Yes
46 76 F Stable Yes Yes No No
26 67 M Stable No No Yes Yes
33 67 M Stable No No Yes Yes
34 58 F Stable No No Yes Yes
23 68 M Unstable Yes Yes No No
4 63 M Unstable No No Yes Yes
6 70 M Unstable Yes No No Yes
10 65 M Unstable Yes No No Yes
28 79 M Unstable No No Yes No
20 65 M Unstable Yes No No No
45 55 M Unstable Yes Yes No Yes
7 75 F Unstable No No Yes No
21 71 M Unstable Yes Yes No Yes
42 73 M Unstable No No Yes No
48 68 M Unstable Yes Yes No Yes
50 66 M Unstable Yes Yes No No
Additional plaques examined by immunohistochemistry
3 73 M Unstable Yes No Yes Yes
29 71 M Stable Yes Yes No No
0 70 M Unstable Yes Yes No Yes
52 77 M Unstable Yes Yes No Yes
54 52 M Unstable No Yes No Yes
58 71 M Unstable Yes Yes No No
5 57 M Unstable Yes Yes No Yes
78 67 F Unstable Yes Yes No No
113 77 M Unstable Yes Yes No No
121 76 M Unstable Yes Yes No Yes
Bold type indicates stable plaques and italicized type indicates unstable plaques whose protein was pooled in the microarray study.
Table 2. Clinical Details of Patients Used in This Study
Patient no. Echo-Doppler Cholesterol Fibrinogen CRP Diabetes
Leukocytes
(103)
22 Hyperecho 6.5 5.5 6.7 No 8.9
46 Hyperecho 3.9 4.5 3.1 Yes 9.7
26 Hyperecho 4.0 4.0 13.6 Yes 9.0
33 Hyperecho 4.1 3.0 2.1 No 8.0
34 Hyperecho 3.9 5.0 61.7 No 10.5
23 Hyperecho 6.5 6.5 1.7 No 4.7
4 Hyperecho 5.4 5.7 2.4 Yes 16.2
6 Hyperecho 4.7 4.1 13.9 Yes 6.1
10 Hypoecho 6.0 3.1 4.9 No 6.6
28 Hypoecho 4.3 4.4 0.9 No 6.5
20 Hypoecho 5.2 3.4 2.2 Yes 6.1
45 Hypoecho 5.3 4.8 1.5 No 9.7
7 Hyperecho 5.9 5.5 86.5 No 3.2
21 Hypoecho 3.9 5.8 0.9 Yes 6.1
42 Hypoecho 6.2 4.1 2.3 No 7.5
48 Hypoecho 4.8 3.5 34.9 No 7.3
50 Hypoecho 4.9 4.1 31.6 No 7.0
Additional plaques examined by immunohistochemistry
3 Hyperecho 4.6 3.5 0.5 No 6.3
29 Hyperecho 4.7 3.3 0.5 No 5.1
40 Hyperecho 4.5 2.2 0.9 Yes 6.3
52 Hypoecho 6.3 3.1 8.0 Yes 5.0
54 Hyperecho 5.4 6.1 0.2 No 5.3
58 Hypoecho 5.1 3.3 0.3 No 5.5
65 Hypoecho 5.3 3.4 4.3 No 9.6
78 Hypoecho 5.1 3.6 1.0 Yes 4.8
113 Hypoecho 2.8 3.2 2.5 No 5.2
121 Hypoecho 5.1 6.5 40.8 No 7.4
Bold type indicates stable plaques and italicized type indicates unstable plaques whose protein was pooled in the microarray study.
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Histology
Sections (5 m) were stained with hematoxylin and eosin.
Individual plaques were defined according to Stary’s
classification,1 and features including rupture, in-
traplaque hemorrhage, vascularity, and lipid content
were identified.
Protein Microarray Analysis
Extraction, labeling, and analysis were based on the
method supplied by BD Biosciences (Clontech). Briefly,
tissue was homogenized directly into extraction/labeling
buffer (supplied) and centrifuged, and the protein con-
centration of the supernatant was measured using the
Bio-Rad assay kit. Individual plaque lysates were diluted
to produce a protein concentration of 1.1 mg/ml, and
three pooled lysates (1 ml) were prepared, each contain-
ing equal protein quantities (250 g) from four separate
plaque samples as follows: A) four stable arteries from
nonsymptomatic patients and B) four unstable arteries
from symptomatic patients. Pooled samples were divided
into two equal portions, and the primary amines of one
portion of each were labeled with Cy3-NHS and the other
with Cy5-NHS fluorescent dyes (90 minutes/4°C). Un-
bound dye was removed by passing the samples through
PD-10 columns, after which the protein content of the
resulting labeled samples was measured. Slide mixtures
were prepared containing 100 g of Cy3-labeled sample
A  100 g Cy5-labeled sample B or vice versa. Slide
mixtures (20 g) were then incubated with pre-prepared
slides for 30 minutes at room temperature with constant
agitation. After washing, slides were dried by centrifuga-
tion and scanned using an Axon Systems, 4200 microar-
ray scanner.
Data analysis was performed using GenePix Pro soft-
ware. The advantages of this technique are as follow. The
antibodies are applied in duplicate to the array, and the
import and analyses method calculates readings based
on a mean of fluorescent readings from both spots,
thereby reducing the chances of assigning false-positive
and false-negative results. 2) Internally normalized ratios
(INRs) are produced based on results from a combina-
tion of the two slides. Hence, allowances are made for
variability between Cy3 and Cy5 labeling efficiencies.
INR is defined as follows:
INR
A-Cy5/B-Cy3
B-Cy5/A-Cy3
relative fluorescence
Average values based on duplicates that differ by
more than 30% were considered invalid. Antigens were
considered more abundant in sample A when INR  1.5
and more abundant in sample B when INR  0.5. Ex-
pression of proteins considered to be deregulated and
relevant to this study were confirmed by Western blotting
using the original labeled protein mixtures.
Western Blotting
A protein lysate containing an equivocated mixture of four
normal carotid artery lysates was prepared, and Western
blotting was used to compare protein expression from
this mixture with those in samples A (stable) and B (un-
stable). Briefly, equal quantities of protein (15 g) were
mixed with 2 Laemmli sample buffer, mixed by vortex-
ing, and boiled in a water bath for 15 minutes. Samples
were separated, along with prestained molecular weight
markers (32 to 200 kd), by 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Proteins were elec-
Table 3. Confirmatory Western Blotting Results Showing Relative Expression of Deregulated Proteins in Carotid Plaque Mixtures
Compared with Normal Arteries
Protein Function Fold change compared to normal artery
Stable Unstable
Caspase-9 Initiator caspase involved in mediating mitochondrion-dependent
apoptosis27
2.5
Cleaved 2.1
Gads Grb2-like adaptor protein associates with T-cell receptor signal
transducer SLP-7646
3.0
GIT1 GPCR kinase interacting protein. Substrate and facilitator for c-
src-mediated responses in vascular SMC34
2.1
HIF1- Activated in macrophages stimulated by oxidized low-density
lipoprotein25
1.5 2.0
JAM-1 EC-associated modulator of tight junctions affecting vascular
permeability45
2.2
JNK Signaling activator of c-jun, inducer of apoptosis/cell growth44 JNK-2 1.5 2.5
JNK-1 1.0 2.1
L-caldesmon Contractile protein increased during dedifferentiation of SMC47 0.3
c-src Signaling molecule that has an important role in mediating SMC
and EC growth36
2.0 3.5
TNF- Inflammatory cytokine associated with elevated expression in
tissue and serum of patients with severe atherosclerosis23
1.5 3.3
TOPO-II- Complexes with cell cycle regulators, affecting chromatin
condensation, and is a strong inhibitor of apoptosis40
1.3 2.0
Cleaved 1.5 2.8
TRAF4 TNFR interacting factor binds to and activates TNFR inducing
inflammation31
1.5 3.5
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Figure 2. A: Western blot showing GADS (34 kd) expression in normal arteries obtained at transplant (lanes 1–3); stable, fibrous arteries (lanes 4 and 6); and
unstable hemorrhagic/ulcerated arteries (lanes 5 and 7–9). Increased expression was seen in the latter. In the bar charts, left represents a comparison against
-actin (loading control), right is with SMC actin, and middle versus EC content (anti-CD105). The mean value for the three normal arteries is presented as N.
B: Immunohistochemical localization of GADS showed weak staining in fibrous regions (i, patient 29), increased expression in macrophages from unstable
regions (ii and iii, arrows; patients 29 and 65, respectively), and association with ECs from hemorrhagic regions (iv, arrows; patient 29). Staining was performed
using the VectaStain ABC kit. Original magnifications (B, i–iv): 10 (left); 40 (middle); and 100 (right).
Figure 1. A:Western blot showing caspase-9 (46 kd) and cleaved caspase-9 (34 kd) expression in normal arteries obtained at transplant (lanes 1–3); stable, fibrous
arteries (lanes 4 and 6); and unstable hemorrhagic/ulcerated arteries (lanes 5 and 7–9). Increased expression was seen in the latter. In the bar charts, left represents
a comparison against -actin (loading control), right is with SMC actin, andmiddle versus EC content (anti-CD105). The mean value for the three normal arteries
is presented as N. B: Immunohistochemical localization of caspase-9 in fibrotic portions of artery showing weak staining (i, patient 58), and in unstable plaques,
showing overexpression in macrophages (ii, arrow; patient 52), SMCs (iii, arrow; patient 3), and ECs (iv, arrows; patient 3) from hemorrhagic regions. v is
a double-labeled section showing caspase-9 association with macrophages (patient 78). Macrophages (anti-CD68) were stained with Vector blue. Staining was
performed using the VectaStain ABC kit. Original magnifications (B, i–v): 10 (left); 40 (middle); and 100 (right).
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troblotted (Hoefer, Bucks, UK) onto nitrocellulose filters (1
hour), and the filters were blocked for 1 hour at room
temperature in Tris-buffered saline (TBS)-Tween (pH 7.4)
containing 1% bovine serum albumin. Nitrocellulose fil-
ters were then stained with primary antibodies directed
toward TNF-, c-src, TRAF4, GIT1, TOPO-II-, JAM-1,
caspase-9, Gads, L-caldesmon, and JNK, diluted 1:1000
in the same blocking buffer, overnight at 4°C on a rotating
mixer. After washing (5  10 minutes in TBS-Tween at
room temperature), filters were stained with either goat
anti-rabbit or rabbit anti-mouse horseradish peroxidase-
conjugated secondary antibodies diluted in TBS-Tween
containing 5% defatted milk (1:1000, 1 hour at room
temperature) with continuous mixing. After a further five
washes in TBS-Tween, proteins were visualized using
enhanced chemiluminescence or ECL Plus chemilumi-
nescent detection. Specificity of antibodies was con-
firmed by application of positive control purified cell pro-
teins, and/or preincubation with inhibitory peptides,
which abolished antibody staining (data not included).
Selected antibodies were used to examine protein ex-
pression in another 12 individual carotid plaque speci-
mens compared with three normal arteries obtained at
transplant. Blots were also stained with anti--actin anti-
bodies as a protein loading control, anti-CD105 (EC
marker), and anti-SMC actin (SMC marker) to determine
the concentrations of individual cellular component within
the plaques.
Semiquantitative analysis of protein concentration from
Western blots was performed using a scanning densi-
tometer (LKB, Bucks, UK). Results accompanying the
figures are given as numerical increase or decrease
compared with the control untreated cells, assigned an
arbitrary optical density of 1.0. Notable increases were
designated 1.5-fold and reductions 0.5-fold com-
pared with the mean values derived from normal carotid
arteries. The intensity of staining between different gels
could not be compared because of variation in enhanced
chemiluminescence development time. All experiments
were repeated at least twice, and a representative exam-
ple is shown.
Immunohistochemistry
Paraffin-processed sections were deparaffinized and re-
hydrated in graded ethanol solutions. Slides were then
rinsed in distilled water and treated with 3% hydrogen
peroxide in methanol (10 minutes at room temperature) to
remove endogenous peroxidase activity. Sections were
placed in Triton-X 100 for 20 minutes before blocking with
goat antiserum (30 minutes at room temperature). Pri-
mary antibodies were then added (TRAF4, 1:100; GIT1,
1:75; c-src, 1:100; TOPO-II-, 1:100; JAM-1, 1:100;
caspase-9, 1:75; Gads, 1:100; and JNK, 1:75) to goat
serum [diluted 1:200 in phosphate-buffered saline
(PBS)], and sections were incubated overnight at 4°C.
After rinsing in PBS, standard Vectastain (ABC) avidin-
biotin peroxidase complex (Vector Laboratories) was ap-
plied, and the slides were incubated at room temperature
for a further 30 minutes. Color was developed using
diaminobenzidine and sections counterstained with he-
matoxylin before dehydration, clearing, and mounting.
Specificity of the immunoreaction was confirmed by a
lack of immunostaining in control sections, in which the
primary antibody was replaced with either PBS or preim-
mune serum, and the secondary antibody was replaced
by an irrelevant antibody or PBS (data not included).
Double Labeling
For double labeling after primary antibody staining and
development, sections were washed in PBS, and a sec-
ond antibody was applied followed by addition of alkaline
phosphatase-labeled polymer and visualization with Vec-
tor Blue substrate. ECs were identified by staining with
anti-CD105, SMCs using anti-SMC-actin, and macro-
phages by anti-CD64 antibodies.
Results
Microarray Analysis
Expression of 512 proteins was compared between
crude cell protein lysates in pooled fibrous, nonulcerated
stable plaques from asymptomatic patients (n  4) and
ulcerated, hemorrhagic unstable plaques from symptom-
atic patients (n  4). Analysis of results, using GenePix
software and the BD Biosciences microarray analysis
workbook, revealed good reproducibility between dupli-
cate spots bound to the same antibody. Less than 0.5%
showed greater than 30% variation between spots (lead-
ing to their elimination from this study). In total, 21 pro-
teins were more highly expressed (INR 0.5) in unstable
plaques, whereas 3 were increased in stable as com-
pared to unstable ones (INR  1.5). Several proteins,
previously shown to be overexpressed in unstable ath-
erosclerotic disease, were notably increased in unstable
plaques in our study, including TNF-, HDJ-2 (heat shock
protein-40; HSP40), and c-reactive protein-2 (CRP-2).
Western Blotting-Microarray Confirmatory
Studies
For Western blot analysis, we chose proteins that were
novel in regard to their expression in atherosclerotic
Figure 3. A:Western blot showing expression of GIT1 (95 kd) expression in normal arteries obtained at transplant (lanes 1–3); stable, fibrous arteries (lanes 4–6);
and unstable hemorrhagic/ulcerated arteries (lanes 7–9). Increased expression was seen in lanes 7–9. In the bar charts, left represents a comparison against -actin
(loading control), right is with SMC actin, and middle versus EC content (anti-CD105). The mean value for the three normal arteries is presented as N. B:
Immunohistochemical localization demonstrated weak staining in normal looking and fibrous regions (i, patient 58) but strong staining in infiltrating macrophages
from ulcerated unstable plaques with high cellular content (ii, arrows; patient 3; iii, patient 52; and iv, patient 28). v is a double-labeled section showing GIT1
association with macrophages (patient 65). Macrophages (anti-CD68) were stained with Vector blue. Staining was performed using the VectaStain ABC kit.
Original magnifications (B, i–v): 10 (left); 40 (middle); and 100 (right).
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plaques and that might be involved in modulation of
inflammatory, angiogenic, proliferative, and apoptotic
pathways leading to plaque destabilization. TNF- and
hypoxia-inducible factor- (HIF1-), which have previ-
ously been reported to be up-regulated in atherosclerotic
plaques, were also identified from our microarray studies
and were further analyzed as internal controls. Mixtures
of proteins aliquotted from samples A and B (pooled
crude protein extracts) were compared with a mixture of
four normal carotid artery protein lysates obtained from
patients at transplant surgery. Relative protein expres-
sion is shown in Table 3. All 11 proteins examined
showed differential expression (10 increased and 1 de-
creased) in plaque samples compared to normal carotid
artery specimens. Notable differences in expression be-
tween stable and unstable plaque mixtures (A and B)
were found for TNF-, TRAF4, Gads, GIT1, Caspase-9,
c-src, TOPO-II-, and JAM-1. Increases in expression
compared to normal artery were also seen in both stable
and unstable artery mixtures stained with anti-TOPO-II-,
total JNK, TRAF4, TNF-, and HIF1-.
Western Blotting and Immunohistochemistry on
Individual Plaques
Highlighted proteins from Table 3 (above) were chosen
for further analysis. Total proteins from 17 carotid plaque
specimens were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and Western blotting
was used to determine the relative expression of test
proteins between normal artery (n 3) and stable (n 5)
and unstable disease (n  12) (Table 2). Immunohisto-
chemistry was performed on paraffin-processed sections
from normal artery and stable and unstable plaques to
identify protein localization. There was no clear associa-
tion between protein expression measured by Western
blotting and plaque histological classification (ie, hemor-
rhagic, ulcerated, and fibrous), symptomatic/asymptom-
atic nature of the disease, or clinical data such as cho-
lesterol, fibrinogen, C-reactive protein, or leukocyte
concentration. The level of protein expression was not
related to the total numbers of SMCs or ECs present in
the plaque samples, although expression of CD105 was
slightly greater in 5 of 12 hemorrhagic/ulcerated plaques,
whereas SMC actin was slightly reduced in 3 of 12.
However, immunohistochemistry analysis demonstrated
specific cellular localization of proteins with hemorrhagic
and ulcerated regions in individual plaques as described
below.
Caspase-9 was increased in 15 of 17 plaque samples
(3 stable and all 12 unstable; 1.5- to 6.1-fold) compared
with normal coronary arteries (Figure 1A). Cleaved
caspase-9 (RMM, 34 kd) was also detected in all 12 of
the unstable plaques and three of five stable ones (1.5- to
2.9-fold compared to control arteries). There was highly
selective staining with this antibody, with positive areas
being close to unstable regions where ulceration and
hemorrhage was visible together with macrophage infil-
trates (Figure 1B). Also there was abundant staining in
microvascular ECs surrounding active regions. There
was no staining in fibrous plaques.
Mona/Gads was not detected by Western blotting in
normal artery or in fibrous, stable plaques; however, 6 of
12 unstable plaques showed overexpression of this pro-
tein (1.9- to 3.5-fold compared to control arteries; Figure
2A). Intense staining of perivascular ECs around small
capillaries, in the intima of SMCs, and in macrophages
was seen in hemorrhagic and ulcerated plaques (Figure
2B).
GIT1 protein expression was increased in 8 of 17
plaques (zero stable and eight unstable) compared to
control arteries (1.6- to 5.5-fold; Figure 3A). This protein
was almost exclusively expressed in macrophages within
the areas of inflammation in ulcerated-hemorrhagic
plaques (Figure 3B). A few ECs were stained, but no
staining was visible in normal tissue or in fibrous plaques.
JAM-1 was expressed weakly in all three normal arter-
ies examined, but notable increases were observed in 13
of 17 plaque samples (3 stable and 10 unstable; 1.5- to
4.8-fold compared with normal arteries; Figure 4A). Small
groups of mononuclear macrophages and lymphocytes
were also stained within active areas of ulcerated-hem-
orrhagic plaques. Weaker staining was also noted in ECs
from these regions (Figure 4B). No staining was visible in
normal artery or fibrous plaques.
JNK (JNK1 and two isoforms) was increased in 12 of
17 plaque samples (three stable and nine unstable) com-
pared with normal artery (JNK1; 1.5- to 3.8-fold and
JNK2; 2.0- to 3.9-fold compared with normal arteries;
Figure 5A). Immunohistochemistry demonstrated in-
creased expression of JNK in macrophages and, to a
lesser degree, in ECs and SMCs (Figure 5B). Generally,
there were smaller numbers of positively stained cells
observed in fibrous plaques.
c-src was expressed weakly in normal artery and over-
expressed in 11 of 17 plaque samples (three stable and
eight unstable; 2.2- to 5.6-fold compared to normal arter-
ies; Figure 6A). More diffuse staining was present with
areas of infiltrating cells, ie, macrophages and lympho-
cytes, and some ECs from selected regions were strongly
positive. Extracellular staining was visible across the un-
stable plaques (Figure 6B). No staining was visible in
fibrous plaques.
Native TOPO-II- was not detected in normal arteries
but was expressed in 4 of 17 plaque tissues (two stable
and two unstable; 1.8- to 2.5-fold compared with control
Figure 4. A: Western blot showing expression of JAM-1 (48 kd) protein in normal arteries obtained at transplant (lanes 1–3); stable, fibrous arteries (lanes 4 and
6); and unstable hemorrhagic/ulcerated arteries (lanes 5 and 7–9). Increased expression can be seen in unstable arteries. In the bar charts, left represents a
comparison against -actin (loading control), right is with SMC actin, and middle versus EC content (anti-CD105). The mean value for the three normal arteries
is presented as N. B: Immunohistochemistry showed weak staining in fibrotic areas (i, patient 29) and increased expression in macrophages (ii, arrows; patient
40) and ECs (iii and iv, arrows; patient 54) from unstable hemorrhagic and ulcerated regions. v is a double-labeled section showing JAM-1 association with ECs
(patient 65). ECs (anti-CD105) were stained with Vector blue. Staining was performed using the VectaStain ABC kit. Original magnifications (B, i–v): 10 (left);
40 (middle); and 100 (right).
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Figure 5. A:Western blot shows expression of JNK (JNK1, 43 kd; JNK2, 51 kd) in normal arteries obtained at transplant (lanes 1–3); stable, fibrous arteries (lanes
4–6); and unstable hemorrhagic/ulcerated arteries (lanes 7–9). Increased expression of both JNK1 and JNK2 was seen in stable and unstable plaques (lanes 4–9)
compared with control arteries (lanes 1–3). In the bar charts, left represents a comparison against -actin (loading control), right is with SMC actin, and middle
versus EC content (anti-CD105). The mean value for the three normal arteries is presented as N. B: Immunohistochemistry showed weak staining of SMCs in
fibrous arteries (i, patient 121) but was strongly expressed by macrophages (ii, arrows; patient 65) and SMCs (iii, arrows; patient 65) in ulcerated and
hemorrhagic plaques. Staining was performed using the VectaStain ABC kit. Original magnifications (B, i–iii): 10 (left); 40 (middle); and 100 (right).
1014 Slevin et al
AJP March 2006, Vol. 168, No. 3
arteries). The truncated form (75 kd) was detected at low
levels in normal artery but was overexpressed in all 17
plaque specimens (2.0- to 3.5-fold compared with normal
arteries; Figure 7A). Immunohistochemistry demon-
strated strong staining of proliferating ECs and SMCs
within areas of neovascularization, from inflammatory re-
gions containing high concentrations of cell infiltrates, in
both hemorrhagic and ulcerated plaques (Figure 7B).
Very weak staining was observed across stable, nonva-
scularized fibrous plaques.
Figure 6. A: Western blot shows expression of c-src in normal arteries obtained at transplant (lanes 1–3); stable, fibrous arteries (lanes 4 and 6); and unstable
hemorrhagic/ulcerated arteries (lanes 5 and 7–9). Increased expression of c-src was seen particularly in unstable plaques (lanes 5 and 7–9) compared with control
arteries. In the bar charts, left represents a comparison against -actin (loading control), right is with SMC actin, and middle versus EC content (anti-CD105).
The mean value for the three normal arteries is presented as N. B: Immunohistochemistry demonstrated weak staining of c-src in fibrous regions (i, patient 28),
and increased immunoreactivity associated with ECs (arrows) and macrophages (broken arrows) from unstable plaque regions (ii, arrows; patient 52; iii and
iv, arrows; patient 54). Staining was performed using the VectaStain ABC kit. Original magnifications (B, i–iv): 10 (left); 40 (middle); and 100 (right).
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TRAF4 was identified and overexpressed in 13 of 17
plaque specimens (3 stable and 10 unstable) compared
to normal artery (1.5- to 9.7-fold; Figure 8A). Normal
looking and fibrous arterial tissue was negative for
TRAF4. In unstable (ulcerated and hemorrhagic) plaques
there was strong staining within microvascular ECs in
Figure 7. A:Western blot shows expression of native Topo-II- (170 kd) in normal arteries obtained at transplant (lanes 1–3); stable, fibrous arteries (lanes 4–6);
and unstable hemorrhagic/ulcerated arteries (lanes 7–9). Increased expression of Topo-II- was seen in the majority of plaques, and the presence of the cleaved
protein (70 kd) can be seen in lanes 6 and 7. In the bar charts, left represents a comparison against -actin (loading control), right is with SMC actin, andmiddle
versus EC content (anti-CD105). The mean value for the three normal arteries is presented as N. B: Immunohistochemistry showed weak staining in fibrous
plaques (i, patient 28) and increased immunoreactivity in ulcerated plaques, particularly associated with ECs (arrows) and SMCs (broken arrows) (ii and iii,
arrows; patient 28). iv is a double-labeled section showing Topo-II- association with SMCs (patient 78, arrows). SMCs (anti-SMC-actin) were stained with Vector
blue. Staining was performed using the VectaStain ABC kit. Original magnifications (B, i–v): 10 (left); 40 (middle); and 100 (right).
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areas of neovascularization, especially close to sites of
rupture. Infiltrating macrophages and lymphocytes from
these areas were also strongly stained. Plaques with the
highest cellular component showed the greatest number
of positive cells (Figure 8B). There was no staining in
fibrous plaques.
Discussion
In this study, we have used microarray technology to
investigate differences in the expression of more than
500 proteins between normal carotid arteries and those
obtained from patients with stable and unstable athero-
sclerotic plaques. Proteomic methodologies such as pro-
tein microarrays and high-throughput Western analysis
have the advantages over gene microarray studies of
avoiding the necessity to validate gene expression pro-
files by real-time reverse transcriptase-polymerase chain
reaction and confirming subsequent protein translation,
which does not always show the expected correlation.20
Although detection of proteins using these arrays is sen-
sitive to nanogram quantities, errors and false-positives
can occur because of nonspecific binding of proteins,
degraded proteins, and/or Cy3/Cy5 fluorescent labels. In
our experiments, these problems were overcome by use
of the BD Bioscience data analysis program, which high-
lighted results in which the duplicate readings were no-
tably different (30%) and identified differences pro-
duced due to differential affinity of Cy3/Cy5 labels to
specific proteins. Secondly, the original Cy-labeled crude
protein lysates were used to confirm differential expres-
sion of relevant proteins by Western blotting. Martinet and
colleagues20 found a high rate of false-positive results
(50%) using high-throughput Western array technol-
ogy, and the effectiveness of our initial screen was reliant
on the quality of all of the individual antibodies. Therefore,
the presence of weakly reacting or nonspecific antibod-
ies could have led to some false-negative or -positive
results. However, several important studies have used
BD Biosciences protein antibody microarrays to great
effect to dissect tumor cell signaling pathways,21 as well
as muscular atrophy-associated proteins,22 thus validat-
ing the usefulness of these arrays. In our study, all 11
proteins identified from the original array showed differ-
ential expression between the stable and unstable
plaque test mixtures, suggesting a high level of specific-
ity of the array antibodies and a potential use for this type
of proteomic analysis in accurate differential identification
of plaque pathogenesis. One limitation of this work was
the overall numbers of proteins studied. Hence, poten-
tially important mediators of plaque development may
have been missed. Future advances in proteomics and
development of larger protein microarrays, when applied
to carotid artery disease, should enable the development
of a more complete understanding of the pathobiology of
unstable plaque formation.
BD Bioscience protein microarrays contain duplicate
printed antibodies raised against numerous proteins as-
sociated with inflammatory, pro/anti-apoptotic, and an-
giogenesis pathways. Our study is the first to compare
global protein expression between stable and unstable
carotid artery disease. Apart from the identification of a
number of novel proteins in atherosclerotic plaques, we
have further validated our microarray results by confirma-
tion of several key proteins, already established as per-
forming a role in development of this disease. These
included TNF-,23 c-reactive protein-2 (CRP-2),24 HIF1-
,25 and HDJ-2 (HSP40)26 (data not included). Because
of the relatively large quantities of protein required for
these arrays, we have used pooled samples in our mi-
croarray experiments. Because only a proportion of the
arterial tissue contained plaque and not all plaques will
over/underexpress the same proteins, some weaker pro-
tein changes (particularly those occurring in only some of
the pooled samples) could have been missed. This may
also explain why the fold differences were relatively
small. Further studies will use laser capture microdissec-
tion technology to dissect out individual plaque compo-
nents, allowing evaluation of the proteins described here
as well as other plaque-specific genes/proteins suitable
for examination using gene microarrays and proteomics
(using SELDI mass spectrometry), respectively.
One of the critical stages of atherosclerotic plaque
development involves changes in the rates of both SMC
and EC proliferation and apoptotic cell death. Identifica-
tion of novel modulators of these processes should help
to improve our understanding of the molecular mecha-
nisms responsible for determining the causes of plaque
thrombosis. An increase in the rate of cellular apoptosis
can result in thinning of the fibrous cap, increased vol-
ume of acellular (weak) tissue, and EC hemorrhage, as
described earlier. Our results demonstrate increased ex-
pression of caspase-9, JNK, and TRAF4, which could be
novel promoters of apoptosis.
Western blotting demonstrated increased expression
of procaspase-9 in all 12 of the unstable plaques exam-
ined, together with three of five stable ones. Increased
expression of cleaved (active) caspase-9 was also de-
tected in these samples. Immunohistochemical analysis
showed that caspase-9 was localized around unstable
plaque regions, particularly in association with microvas-
cular ECs surrounding active regions. Caspase-9 is one
of the initiator caspases responsible for mitochondrion-
dependent apoptosis after formation of the apoptosome
and could be a key determinant in the development of
hemorrhagic microvessels associated with unstable
plaque tissue.27 Furthermore, we identified expression of
caspase-9 in macrophages from the same regions. In-
creased apoptosis of macrophages may be a key indi-
cator of lesional instability and plaque rupture, for exam-
ple after intracellular accumulation of cholesterol.28
TRAF4 is involved in p53-mediated proapoptotic sig-
naling.29 Overexpression of TRAF4 induced apoptosis in
temperature-dependent cell lines (Vm10, M3) in associ-
ation with activation of p53. TFAF4 has also been identi-
fied as a binding partner for p47phox in ECs, whereas
co-expression of TRAF4 and p47phox led to JNK activa-
tion and an increase in the production of oxidants.30 The
results presented here, demonstrated increased expres-
sion of TRAF4 in 10 of 12 unstable plaques examined.
Immunohistochemistry showed TRAF4-positive cells
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were mainly microvessel ECs from ulcerated and hemor-
rhagic regions. Macrophages were also positively
stained. Generally, TNF--induced inflammatory re-
sponses occur in vascular regions exposed to disturbed
flow and activate MAP kinase pathways (JNK and p38)
after TNF-receptor binding to TRAFs.31 TRAF4 may be a
novel mediator of EC and macrophage apoptosis, creat-
ing destabilized areas of plaque tissue.
Various models of atherosclerosis and cell activation
have demonstrated an important role for JNK activation in
SMC apoptosis16 and EC mitogenesis, for example, via
TNF--induced TRAF-SEK1 signaling pathways.32 Ex-
pression of JNK was increased in the majority of plaque
samples that we examined. Increased expression of JNK
could enhance blood vessel formation in hemorrhagic
areas, whereas overexpression in SMCs could increase
the rate of apoptosis, thus contributing to development of
unstable regions. It was recently demonstrated that ath-
erosclerosis-prone ApoE/ mice lacking JNK2 devel-
oped less atherosclerosis than the controls, and macro-
phages lacking JNK2 displayed suppressed foam cell
formation.33 Pharmacological inhibition of JNK efficiently
reduced plaque formation in this murine model, suggest-
ing that JNK may have an important role in development
of unstable atherosclerosis via macrophage activation.
Cell signaling molecules c-src and GIT1 were also
overexpressed in both ECs and macrophages from un-
stable hemorrhagic and ulcerated regions. GIT1 is a
novel scaffold protein, recently shown to facilitate c-src-
mediated MEK1 activation in a variety of cells and thus to
mediate mitogenesis.34 Lipid mediators of EC prolifera-
tion, including sphingosine-1-phosphate, also appear to
enhance vascular barrier function through paxillin-GIT1
interactions, suggesting a possible protective influence
on protection against atherosclerosis by maintenance of
vascular permeability.35 Although activation of c-src oc-
curs in vitro, for example, after treatment of vascular
SMCs with the potent vasoconstrictor urotensin II,36 we
were not able to show increased expression of this pro-
tein in SMCs from unstable carotid plaque regions, al-
though the activation status of c-src was not determined.
JAM-1 is an immunoglobulin superfamily (IgSF) trans-
membrane receptor that can be expressed by blood
platelets, ECs, epithelial cells, macrophages, and neutro-
phils. It is localized at EC-cell tight junctions and has an
important role in modulating vascular homeostasis and
leukocyte/monocyte transmigration across ECs. It can
promote FGF-2-induced EC migration on vitronectin
through intracellular signaling involving v3 integrin.
37
Blocking of the extracellular domain of JAM-1 inhibits
FGF-2-induced proliferation and angiogenesis of human
umbilical vein ECs.38 We saw a dramatic up-regulation of
this protein in macrophages and also associated with
blood vessels in hemorrhagic and ulcerated plaque re-
gions. Blocking anti-JAM-1 antibodies were able to inhibit
monocyte filtration and attenuate cytokine-induced men-
ingitis in mice.39 These results suggest that pharmaco-
logical inhibition of JAM-1 expression might be of benefit
in patients with atherosclerotic plaques by reducing the
infiltration of macrophages.
TOPO-II- is a cell-cycle-related marker normally
found in the nucleus of cells and required for chromo-
some segregation during mitosis. Topoisomerase inhibi-
tors are strong inducers of apoptosis, whereas up-regu-
lation of TOPO-II- gene expression results in increased
mitosis and cell proliferation.40 A proteolytically cleaved
(70 kd) form of Topo-II- has been shown in both the
membrane and the nucleolus of cells undergoing necro-
sis and apoptosis.41 In our study, increased expression
of cleaved TOPO-II- was seen by Western blotting in the
majority of plaque samples, whereas the native protein
was also increased in several plaques compared with
normal artery. Immunohistochemistry revealed an in-
crease in expression of TOPO-II- in both ECs and SMCs
from hemorrhagic and ulcerated regions of unstable
plaques, in particular, in regions undergoing neovascu-
larization. One study has revealed a strong anti-prolifer-
ative effect of Topotecan (a potent TOPO-1 inhibitor) on
coronary vascular SMCs even in the presence of growth
factors. These data suggests that topoisomerases
may have a role in induction or maintenance of SMC
and EC proliferation associated with arterial plaque
development.42
Mona/Gads is a Grb2-related Src homology 3 (SH3)
and SH2 domain-containing adapter protein, expression
of which is restricted to cells of hematopoietic lineage, in
particular monocytes and T lymphocytes. Very little is
known about the involvement of Gads in disease progres-
sion, and it has not previously been identified in associ-
ation with atherosclerotic lesions. It has been shown that
Gads is induced during monocyte/macrophage differen-
tiation after interaction with macrophage colony-stimulat-
ing factor receptor (M-CSFR),43 making it a potential
mediator of macrophage differentiation in atherosclero-
sis. Our results demonstrated a strong up-regulation of
this protein in macrophage infiltrates from inflammatory
regions of unstable hemorrhagic and ulcerated plaques.
Increased Gads expression may therefore be an impor-
tant mediator of monocyte differentiation, occurring dur-
ing unstable plaque development.
In conclusion, using protein microarray technology, we
have identified proteins overexpressed in developing ar-
terial plaques, in particular in association with ECs and
SMCs from unstable hemorrhagic ulcerated regions.
Their role in development of this disease is currently
being studied. Our follow-up studies will aim to determine
Figure 8. A: Western blot shows expression of TRAF4 in normal arteries obtained at transplant (lanes 1–3); stable, fibrous arteries (lanes 4 and 6); and unstable
hemorrhagic/ulcerated arteries (lanes 5 and 7–9). Increased expression of TRAF4 was seen in unstable plaques compared with control arteries and stable plaques.
In the bar charts, left represents a comparison against -actin (loading control), right is with SMC actin, and middle versus EC content (anti-CD105). The mean
value for the three normal arteries is presented as N. B: Immunohistochemistry showed weak staining of TRAF4 in fibrotic areas of arteries (i, patient 29) but strong
expression in blood vessels (arrows) and infiltrating lymphocytes and macrophages (broken arrows) from unstable hemorrhagic plaques (ii and iii, arrows;
patient 40; iv, arrows; patient 54). v is a double-labeled section showing TRAF4 association with ECs (patient 78, arrows). ECs (anti-CD105) were stained with
Vector blue. Staining was performed using the VectaStain ABC kit. Original magnifications (B, i–v): 10 (left); 40 (middle); and 100 (right).
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their involvement in EC and SMC activation and/or sur-
vival and to identify associated cellular signaling mech-
anisms. Understanding the molecular mechanisms re-
sponsible for initiation of mitogenesis, angiogenesis, and
apoptosis should provide the basis for development of
new therapeutic treatments, perhaps using gene trans-
fection technology to prevent or slow the rate of progres-
sion of this disease. The results presented in this study
are preliminary findings, and although we have confirmed
that these proteins are overexpressed by individual cells
within unstable plaques, the role of these proteins is
speculative, being based on their known functions within
other cell systems. Our ongoing studies using primary
ECs and SMCs are attempting to characterize the effects
of this protein overexpression on cell survival, activation,
and angiogenesis, as well as the signal transduction
mechanisms associated with these processes. We antic-
ipate that future work might examine the role of these
proteins in development of atherosclerosis using in vivo
models. Noninvasive diagnosis and prognosis of patients
with the highest risk of developing symptomatic disease
would represent an important advancement in our ability
to reduce the incidence of coronary heart disease and
stroke. Novel proteins identified here might be useful
serum markers of disease status and could form part of a
future protein microarray panel used to identify patients
at risk of thrombosis as well as to predict treatment out-
come and follow-up.
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